[Quasispecies and mutation of hepatitis B virus polymerase gene in lamivudine- treated patients]

Zhonghua Gan Zang Bing Za Zhi. 2003 Apr;11(4):235-8.
[Article in Chinese]

Abstract

Objective: To study the quasispecies and mutation features of hepatitis B virus polymerase (HBV P) gene in chronic hepatitis B patients before and after lamivudine treatment.

Methods: The HBV P gene was amplificated with PCR and cloned, then single strand conformation polymorphism / heteroduplex analysis (SSCP/HDA) was applied to analyze the quasispecies complexity and mutation characters of HBV P gene.

Results: The quasispecies number of HBV P gene before treatment was larger than that after treatment (7 to 14 vs. 4 to 8, t = 3.98, P < 0.05). Six patients had one or two predominant quasispecies before therapy, but the percentages of predominant quasispecies were lower than those after therapy (33.3% to 81.8% vs. 78.8% to 90.9%, t = 3.42, P < 0.05). By sequencing the predominant clones, there were 2 patients with M550V/L528M mutation, 3 patients with M550I mutation and 1 patient with wild type after lamivudine therapy. Additionally, there were individualization mutations which had no obvious tender.

Conclusion: Quasispecies of hepatitis B virus are changed under the selection of lamivudine, meanwhile, the mutation at YMDD motif emerges.

Publication types

  • English Abstract

MeSH terms

  • Antiviral Agents / therapeutic use
  • DNA, Viral / metabolism
  • DNA-Directed DNA Polymerase / genetics
  • Female
  • Hepatitis B virus / classification
  • Hepatitis B virus / genetics*
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / virology
  • Humans
  • Lamivudine / therapeutic use*
  • Male
  • Point Mutation / genetics*

Substances

  • Antiviral Agents
  • DNA, Viral
  • Lamivudine
  • DNA-Directed DNA Polymerase